226 related articles for article (PubMed ID: 32440843)
21. Urinary Concentrations of Colistimethate and Formed Colistin after Intravenous Administration in Patients with Multidrug-Resistant Gram-Negative Bacterial Infections.
Luque S; Escaño C; Sorli L; Li J; Campillo N; Horcajada JP; Salas E; Grau S
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559275
[TBL] [Abstract][Full Text] [Related]
22. In vitro synergistic activity of colistin and ceftazidime or ciprofloxacin against multidrug-resistant clinical strains of Pseudomonas aeruginosa.
D'Souza BB; Padmaraj SR; Rekha PD; Tellis RC; Prabhu S; Pothen P
Microb Drug Resist; 2014 Dec; 20(6):550-4. PubMed ID: 25055029
[TBL] [Abstract][Full Text] [Related]
23. Characterisation and risk factor profiling of Pseudomonas aeruginosa urinary tract infections: pinpointing those likely to be caused by multidrug-resistant strains.
Tumbarello M; Raffaelli F; Peghin M; Losito AR; Chirico L; Giuliano G; Spanu T; Sartor A; Fiori B; Bassetti M
Int J Antimicrob Agents; 2020 Apr; 55(4):105900. PubMed ID: 31931150
[TBL] [Abstract][Full Text] [Related]
24. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
Hu YF; Liu CP; Wang NY; Shih SC
BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
[TBL] [Abstract][Full Text] [Related]
25. Successful treatment of extensively drug-resistant Pseudomonas aeruginosa osteomyelitis using a colistin- and tobramycin-impregnated PMMA spacer.
Krajewski J; Bode-Böger SM; Tröger U; Martens-Lobenhoffer J; Mulrooney T; Mittelstädt H; Russlies M; Kirchner R; Knobloch JK
Int J Antimicrob Agents; 2014 Oct; 44(4):363-6. PubMed ID: 25182711
[TBL] [Abstract][Full Text] [Related]
26. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: epidemiology and treatment options.
Obritsch MD; Fish DN; MacLaren R; Jung R
Pharmacotherapy; 2005 Oct; 25(10):1353-64. PubMed ID: 16185180
[TBL] [Abstract][Full Text] [Related]
27. Ceftolozane-tazobactam vs. colistin for the treatment of infections due to multidrug-resistant Pseudomonas aeruginosa: a multicentre cohort study.
Almangour TA; Aljabri A; Al Musawa M; Almohaizeie A; Almuhisen S; Damfu N; Alfozan A; Alraddadi BM; Alattas M; Qutub M; Alhameed AF; Khuwaja M; Alghamdi A; Binkhamis KM; Alfahad W; AlShahrani FS
J Glob Antimicrob Resist; 2022 Mar; 28():288-294. PubMed ID: 35121161
[TBL] [Abstract][Full Text] [Related]
28. Antimicrobial activity of ceftolozane-tazobactam against multidrug-resistant and extensively drug-resistant Pseudomonas aeruginosa clinical isolates from a Spanish hospital.
López-Calleja AI; Morilla Morales E; Nuñez Medina R; Fernández Esgueva M; Sahagún Pareja J; García-Lechuz Moya JM; Ferrer Cerón I; Viñuelas Bayon J; Rezusta López A
Rev Esp Quimioter; 2019 Feb; 32(1):68-72. PubMed ID: 30547503
[TBL] [Abstract][Full Text] [Related]
29. In vitro efficacy of colistin against multi-drug resistant Pseudomonas aeruginosa by minimum inhibitory concentration.
Gill MM; Rao JU; Kaleem F; Hassan A; Khalid A; Anjum R
Pak J Pharm Sci; 2013 Jan; 26(1):7-10. PubMed ID: 23261721
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis.
Durakovic N; Radojcic V; Boban A; Mrsic M; Sertic D; Serventi-Seiwerth R; Nemet D; Labar B
Intern Med; 2011; 50(9):1009-13. PubMed ID: 21532223
[TBL] [Abstract][Full Text] [Related]
31. Ceftolozane/tazobactam for the treatment of multidrug resistant Pseudomonas aeruginosa: experience from the Balearic Islands.
Díaz-Cañestro M; Periañez L; Mulet X; Martin-Pena ML; Fraile-Ribot PA; Ayestarán I; Colomar A; Nuñez B; Maciá M; Novo A; Torres V; Asensio J; López-Causapé C; Delgado O; Pérez JL; Murillas J; Riera M; Oliver A
Eur J Clin Microbiol Infect Dis; 2018 Nov; 37(11):2191-2200. PubMed ID: 30141088
[TBL] [Abstract][Full Text] [Related]
32. In vitro activity of polymyxins in combination with β-lactams against clinical strains of Pseudomonas aeruginosa.
Mitsugui CS; Tognim MC; Cardoso CL; Carrara-Marroni FE; Botelho Garcia L
Int J Antimicrob Agents; 2011 Nov; 38(5):447-50. PubMed ID: 21872449
[TBL] [Abstract][Full Text] [Related]
33.
Goodlet KJ; Nicolau DP; Nailor MD
Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923865
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness and Safety of Beta-Lactam Antibiotics with and without Therapeutic Drug Monitoring in Patients with Pseudomonas aeruginosa Pneumonia or Bloodstream Infection.
Kunz Coyne AJ; Alshaer M; Casapao AM; Venugopalan V; Isache C; Ferreira J; Jankowski CA
Antimicrob Agents Chemother; 2022 Oct; 66(10):e0064622. PubMed ID: 36073943
[TBL] [Abstract][Full Text] [Related]
35. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia.
Khawcharoenporn T; Chuncharunee A; Maluangnon C; Taweesakulvashra T; Tiamsak P
Int J Antimicrob Agents; 2018 Dec; 52(6):828-834. PubMed ID: 30236956
[TBL] [Abstract][Full Text] [Related]
36. Characterization of the onset and consequences of pneumonia due to fluoroquinolone-susceptible or -resistant Pseudomonas aeruginosa.
Paladino JA; Sunderlin JL; Forrest A; Schentag JJ
J Antimicrob Chemother; 2003 Sep; 52(3):457-63. PubMed ID: 12888598
[TBL] [Abstract][Full Text] [Related]
37. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients.
Mastoraki A; Douka E; Kriaras I; Stravopodis G; Manoli H; Geroulanos S
Surg Infect (Larchmt); 2008 Apr; 9(2):153-60. PubMed ID: 18426347
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections.
Montero M; Horcajada JP; Sorlí L; Alvarez-Lerma F; Grau S; Riu M; Sala M; Knobel H
Infection; 2009 Oct; 37(5):461-5. PubMed ID: 19499183
[TBL] [Abstract][Full Text] [Related]
39. Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria.
Moriyama B; Henning SA; Neuhauser MM; Danner RL; Walsh TJ
Ann Pharmacother; 2009 Jul; 43(7):1324-37. PubMed ID: 19584386
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of meropenem extended infusion vs intermittent bolus monotherapy and in combination with colistin against Pseudomonas aeruginosa biofilm.
Benavent E; Ulldemolins M; El Haj C; Rigo-Bonnin R; Yu H; Wang L; Wickremasinghe H; Ariza J; Murillo O
Int J Antimicrob Agents; 2023 Aug; 62(2):106856. PubMed ID: 37211260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
